Strategic Collaboration Between Harbour BioMed and Lannacheng
Harbour BioMed (HKEX: 02142), a pioneering biopharmaceutical company, has embarked on an exciting long-term strategic collaboration with Yantai Lannacheng Biotechnology Co., Ltd. Together, these two forward-thinking companies aim to revolutionize the field of oncology by developing next-generation radionuclide drug conjugates (RDCs). This innovative partnership harnesses the strengths and resources of both entities to lead advancements in effective cancer therapy.
Understanding Radionuclide Drug Conjugates
Radionuclide drug conjugates are a promising approach in cancer treatment that combines the specificity of targeted therapy with the potency of radiotherapy. Unlike conventional methods, RDCs use tumor antigen-specific ligands to deliver radionuclides right to the cancer cells. This focused delivery minimizes damage to healthy tissues surrounding the tumor, an essential factor in successful cancer treatment.
A vital aspect of RDCs is their ability to affect adjacent tumor cells and the microenvironment. Even cells that do not exhibit the target antigen can still be impacted by the cytotoxic effects of the radionuclides. This unique mechanism provides an advantage in overcoming challenges associated with tumor heterogeneity and drug resistance, paving the way for healthier outcomes.
Innovative Technologies of Harbour BioMed
Harbour BioMed has established itself as a leader in antibody discovery through its proprietary platforms, including Harbour Mice®. This groundbreaking technology allows for the creation of fully human monoclonal antibodies in various formats, eliminating the need for extensive humanization or engineering processes. The HCAb format, in particular, generates smaller antibodies that excel in specificity, stability, and tissue penetration.
This cutting-edge technology supports the efficient development of RDCs by ensuring that fully human antibodies demonstrate low immunogenicity, enhancing targeted delivery. The therapeutic efficacy can be significantly improved, resulting in reduced drug-related toxicity and side effects, which is crucial for patient safety and treatment success.
Lannacheng's Role in the Collaboration
Founded recently, Lannacheng is driven by a mission to innovate within the oncology space, focusing on theranostic radiopharmaceuticals. With a robust R&D engine that utilizes bespoke pharmacokinetic optimization and dual-targeting drug development platforms, Lannacheng targets the entire development cycle of radiopharmaceutical candidates.
By joining forces with Harbour BioMed, Lannacheng can enhance its capabilities in developing and commercializing radiopharmaceuticals. The incorporation of advanced R&D resources and a dependable supply of radioisotopes plays a significant role in ensuring a resilient and scalable pipeline for innovative cancer therapies.
Vision for the Future
Both companies are enthusiastic about the synergies this partnership will produce. Jingsong Wang, MD, PhD, the Founder and CEO of Harbour BioMed, articulated the excitement behind the collaboration, emphasizing their shared commitment to advancing cancer therapy. He stated that the integration of Harbour BioMed's antibody discovery expertise with Lannacheng's radiopharmaceutical strengths is expected to fast-track the development of effective treatment options.
Similarly, Wu Xiaoming, General Manager of Lannacheng, expressed satisfaction in combining their technological advancements with Harbour BioMed's deep understanding of antibody therapeutics. This collaboration is set to influence the global landscape of oncology treatments significantly.
About Harbour BioMed
Harbour BioMed (HKEX: 02142) focuses on creating novel antibody therapeutics with applications in immunology and oncology. The company is dedicated to building a rich and diverse pipeline through internal capabilities and strategic collaborations, positioning itself as an innovator in the biopharmaceutical field.
About Yantai Lannacheng Biotechnology Co., Ltd.
Established in 2021, Lannacheng specializes in the development of integrated theranostic radiopharmaceuticals targeting oncology. Their advanced technological platforms aim to enhance drug efficacy through improved pharmacokinetic profiles and tailored drug candidates.
Frequently Asked Questions
What is the purpose of the collaboration between Harbour BioMed and Lannacheng?
The collaboration aims to advance the development of next-generation radionuclide drug conjugates for effective cancer therapies.
What are radionuclide drug conjugates?
Radionuclide drug conjugates (RDCs) are targeted cancer therapies that deliver radionuclides directly to tumors, minimizing damage to healthy tissues.
What technologies does Harbour BioMed employ?
Harbour BioMed utilizes advanced technologies like the Harbour Mice® platform to create fully human monoclonal antibodies for enhanced therapy effectiveness.
What is Lannacheng's focus in the biotechnology field?
Lannacheng focuses on developing theranostic radiopharmaceuticals aimed at improving oncology treatments through innovative R&D efforts.
How will this collaboration impact cancer treatment?
This partnership is expected to accelerate the development of more effective and safer cancer therapies, providing new hope to patients worldwide.
